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Abstract
Background:
Extra-fine particle formulations of inhaled corticosteroid (ICS) are associated with improved 
lung delivery. 
Objectives:
A pragmatic study to assess patient reported outcomes after switching from fine to extra-fine 
particle ICS in persistent asthma.
Methods:
24 patients (Mean age 48 year, FEV1 84%, ACQ 1.67) received 4 weeks run-in with a constant 
dose of fine particle ICS (mean dose 710 µg), followed by switching to an equivalent dose of 
extra fine particle hydrofluoroalkane beclomethasone dipropionate (mean dose 355µg). 
Asthma control questionnaire (ACQ), the primary outcome, and mini asthma quality of life 
questionnaire (mAQLQ) were measured pre and post run-in (baseline) and after 4 weeks and 
8 weeks of switching. 
Results:
Comparing pre vs post run-in there were no differences for ACQ: 1.67 vs 1.65 or AQLQ: 5.08 
vs 5.34. There were mean (95%CI) improvements (P<0.001) from baseline after 8 weeks for 
ACQ: -0.53 (-0.83, -0.23) and AQLQ: 0.69 (0.35, 1.04), which exceeded the minimal clinically 
important difference (MCID) of 0.5 for both. There were also differences (P<0.05) in domiciliary 
symptoms and reliever use. There were no significant changes at 8 weeks in lung function, 
FeNO or blood eosinophils. 
Conclusions:
Pragmatic switching from fine to extra-fine particle ICS at half the dose was associated with 
clinically relevant improvements in asthma control and quality of life, but not lung function or 
type 2 biomarkers.
Trial Registration:
EUDRACT (2012-003923-39) and Clintrials.gov (NCT01894048)
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Introduction 
There are presently two hydrofluoroalkane (HFA) solution based pressurised metered dose 
inhaler (pMDI) formulations of inhaled beclometasone dipropropionate (BDP) available in the 
Europe. One is a fine particle formulation with a mass median aerodynamic diameter (MMAD) 
of 2.9µm (Clenil Modulite, Chiesi Ltd, Manchester, UK) and the other extra-fine particle 
formulation with MMAD of 1.1µm (Qvar, Teva UK Ltd, Harlow, UK). The extra-fine particle 
HFA-BDP formulation is associated with improved total and regional lung delivery, which in 
turn translates in being able to use half the dose to achieve the same improvement in forced 
expiratory volume in 1 second (FEV1).[1, 2] 
Patient reported outcomes (PRO’s) include asthma quality of life questionnaire (AQLQ) and 
asthma control questionnaire (ACQ), both of which have minimal clinical important difference 
(MCID) of 0.5.[3, 4] The cut point for ACQ between well controlled and not well controlled  is 
1.0.[5] We wanted to know if ACQ and AQLQ might improve after switching from fine particle 
to extra-fine particle ICS in a group of uncontrolled patients with ACQ>1.0. In order to evaluate 
this we converted patients with persistent asthma to fine particle ICS formulations comprising 
HFA-BDP, fluticasone propionate or budesonide over a run-in period of at least 4 weeks where 
the dose was kept constant, prior to switching to extra-fine particle HFA-BDP at half the dose 
over the subsequent 8 weeks. We elected to power the study on change in ACQ score as we 
use this routinely to follow control in our NHS clinic and it has also been shown to a strong 
predictor of future asthma exacerbations.[6, 7]
Another sensitive marker of response to ICS is airway hyper-responsiveness (AHR) using 
indirect acting challenge with mannitol,[8] which in turn is related to asthma exacerbations.[9] 
It has previously been shown that titrating the ICS dose over one year against mannitol AHR 
results in significantly better control compared to a reference strategy based on lung function, 
symptoms and reliever use.[10] Similar findings have been reported with direct acting 
methacholine challenge in regard to ICS titration and improved control.[11]  Another study with 
extra-fine particle HFA-BDP at half the dose compared to fine particle CFC-BDP demonstrated 
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a significant reduction in air trapping after methacholine challenge using high resolution 
computerised tomography  (HRCT) scanning.[12] 
Hence in the present pragmatic study we also measured AHR in a subgroup of patients who 
after taking a constant dose of ICS at the end of the run-in were identified as being mannitol 
responders at baseline. We wished to see in this subgroup if putative improvements in PRO’s 
were accompanied by commensurate changes in mannitol AHR after switching to extra-fine 
particle HFA-BDP.
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Methods 
We enrolled patients with persistent asthma aged 18-70 years, taking up steps 2, 3 or 4 of 
British Thoracic Society guidelines, with an ICS dose up to 2000ug/day (as fine particle HFA-
BDP equivalent dose) with or without long acting β2 adrenoceptor agonist (LABA), long acting 
muscarinic antagonists (LAMA), leukotriene receptor antagonist (LTRA) or theophylline. 
Patients were required to have FEV1 of at least 60% predicted and an ACQ score of at least 
1.0. At screening patients were requested to stop any LABA and were then converted to fine 
particle ICS either as HFA-BDP (Clenil Modulite pMDI, Chiesi Ltd, Manchester, UK), 
fluticasone propionate (GlaxoSmithKline, Uxbridge, UK)   or budesonide (AstraZeneca, Luton, 
UK) for the subsequent step down and run-in phases. For example during the run-in after 
stopping LABA, patients taking fluticasone/salmeterol were converted to the same dose of 
fluticasone alone. The fine particle ICS dose was permitted to be halved if patients 
subsequently had an ACQ score <1.0, until a minimum Clenil equivalent dose of at least 200µg 
per day was reached. In order words, patients entered the subsequent run-in period with 
partial control – ie ACQ ≥ 1. Patients were then entered into a run-in period of at least 4 weeks 
on a stable fine particle ICS dose and an ACQ score of at least 1.0 at the baseline visit post 
run-in (Figure 2). InPatients continued for the rest of the study on any other second line 
controllers apart from LABA.
At baseline patients were then switched to half the Clenil equivalent dose as extra-fine particle 
Qvar which was continued unchanged over the subsequent 8 week period. 
Visits were performed pre and post run-in (baseline) and after 4 and 8 weeks of switching, 
where measurements were made of ACQ, mAQLQ, spirometry, impulse oscillometry, 
fractional exhaled nitric oxide (FeNO) and blood eosinophils. 
A subgroup of patients who were identified at baseline (after run in) as being responsive to 
mannitol (Osmohale, Pharmaxis, Sydney, Australia) had further challenges performed at 4 
and 8 weeks after switching. Mannitol sensitivity was expressed as the provocative dose 
required to produce a 15% fall in FEV1 (PD15 threshold in mg) calculated by interpolation of 
the log linear dose response curve up to maximum cumulative dose of 635mg. Mannitol 
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reactivity was expressed as the response dose ratio (RDR as % fall /mg) calculated by dividing 
the maximum % fall in FEV1 by the final mannitol dose. Data for PD15 and RDR were 
logarithmically transformed prior to analysis. 
Impulse oscillometry (IOS) was measured using a Jaeger Masterscreen (Jaeger Hochberg, 
Germany) in triplicate using a nose clip lips sealed tightly, cheeks held and with quiet tidal 
breathing for 30s. A Superspiro spirometer (Micro Medical ltd, Chatham, UK) was used to 
record in triplicate according to European Respiratroy Society guidelines. FeNO was 
measured with a NIOX Mino (Aerocrine AB, Solna, Sweden) in accordance with published 
guidelines. 
A domiciliary diary card was recorded for peak flow, symptoms and reliever use. Full informed 
written consent was obtained from all patients and the study was approved by the Tayside 
committee for medical ethics (13/ES/0064) and the study was registered at EUDRACT (2012-
003923-39) and Clintrials.gov (NCT01894048).
Statistical analysis 
The data were initially inspected to assess if they conformed to a normal distribution. 
Outcomes which were non-normally distributed (FeNO, eosinophils, mannitol PD15 and RDR) 
were then log transformed prior to analysis. A comparison of values for post run-in (baseline) 
and at 4 weeks and 8 weeks after switching was performed by repeated measures analysis 
of variance (ANOVA). Post hoc analysis was done for ACQ and mAQLQ by pairwise testing 
using Bonferroni corrected p values. For the subgroup of mannitol responders an overall 
ANOVA was performed but without post hoc pairwise testing to avoid confounding the alpha 
error due to small sample size. The study was designed with at least 80% power to detect a 
0.4 unit change in the primary outcome of ACQ at 8 weeks, assuming a standard deviation of 
0.68, with an alpha error (two tailed) of 0.05, requiring at least 23 patients to complete per 
protocol. Domiciliary diary card data were calculated using the rolling average values from last 
week of the run-in while on fine particle ICS and compared to the eighth week while taking 
extra-fine particle HFA-BDP.
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Results 
The flow of participants is depicted in the CONSORT diagram (Figure 1). 24 patients 
completed per protocol: mean age 48 yr, FEV1 84% predicted, ACQ 1.67, BMI 31.1. 12 
patients were atopic on skin prick testing and all were non-smokers. Mean Clenil equivalent 
dose was 740µg at screening (ie prior to step down) with 15 patients taking concomitant LABA, 
6 on LTRA, 2 on LAMA and 1 on theophylline. During run-in there were 14 patients taking fine 
particle HFA-BDP, and 10 patients on either fine particle fluticasone or budesonide. 4, 5 and 
15 patients were on GINA steps 2, 3, and 4 asthma treatment respectively.  After step down, 
the mean Clenil equivalent dose was 710µg/day which was maintained unchanged throughout 
the run-in period. Following the run in period (ie at baseline) patients were then converted to 
a mean Qvar equivalent dose of 355µg/day. 
There were no differences in mean values comparing pre and post run-in (Table 1) for ACQ 
(1.67 versus 1.65) or mAQLQ (5.08 versus 5.34). Type 2 biomarkers were significantly 
(P<0.05) reduced comparing pre and post run-in values (as mean % difference) for FeNO: -
25% (95%CI -40,-7), and blood eosinophils -24% (95%CI -36,-9). There were no significant 
differences between pre and post run-in values for spirometry or IOS. 
After switching there were significant (P<0.001) mean (95% confidence interval) 
improvements from baseline after 8 weeks for ACQ: -0.53 (95%CI -0.83, -0.23) and mAQLQ: 
0.69 (95%CI 0.35, 1.04), which exceeded the MCID’s of 0.5 for both (Figure 3). Individual 
responder analysis showed that after 8 weeks there were 11/24 (46%) who had a change in 
ACQ>0.5 and 11/24 (46%) who had a change in mAQLQ >0.5 (Figure 4). Individual mAQLQ 
domains showed significant improvements which exceeded the MCID for symptoms 
(P<0.001), emotional function (P<0.01), and environmental stimuli (P<0.01) but not for activity 
limitation (Figure 5) .There were no significant changes in lung function, FeNO or eosinophils 
after switching compared to baseline (Table 2).
In the subgroup of 8/24 patients who responded to mannitol after the run-in at baseline, there 
were significant (P<0.001) overall effects on mannitol sensitivity as PD15. After switching there 
was a 1.59 (95%CI 0.29, 2.89) doubling dose shift in PD15 at 8 weeks (Figure 6). For mannitol 
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reactivity as RDR the overall effect was also significant (P<0.05). In this subgroup there were 
also significant mean improvements comparing 8 weeks versus baseline for ACQ: mean 
difference -0.82 (95%CI -1.59,-0.05), P<0.05 and mAQLQ: mean difference 1.09 (95%CI 0.14, 
2.05), P< 0.05, which exceeded the MCID’s for both.
Diary card data showed no significant changes in morning or evening peak expiratory flow 
(PEF) measurements. There were significant (P<0.05) improvements in domiciliary morning 
and evening symptoms as well as evening reliever use after 8 weeks compared to baseline 
(Table 3).
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Discussion 
The results of the present pragmatic study showed that in uncontrolled asthma patients taking 
fine particle ICS, subsequent switching to half the dose of extra-fine particle HFA-BDP resulted 
in significant improvements in the primary outcome of asthma control as ACQ along with 
asthma specific quality of life as AQLQ. The magnitude of observed changes in ACQ and 
AQLQ can be considered as being clinically relevant as they both exceeded their respective 
MCID’s of 0.5.[3, 4] Responder analysis identified 46% of patients who achieved a change in 
ACQ and AQLQ which exceeded the MCID after 8 weeks. AQLQ domains aside from activity 
limitation also significantly improved by more than the MCID. Domiciliary data showed 
significant improvements in symptoms and reliever use. Moreover, after switching no 
significant changes were seen for either lung function or type 2 inflammatory biomarkers. 
We originally hypothesised that improved regional lung distribution with extra-fine particle 
HFA-BDP [1] might lead to improved PRO’s and would be reflected in commensurate changes 
in small airways function.  We were therefore surprised to see no significant changes in 
impulse oscillometry (IOS) after switching, especially for R5-R20 for AX which emulate 
changes in small airways.[13, 14] The lack of any signal could be due to IOS being more 
sensitive in ICS naïve patients,[15] whereas in our study patients had  been taking at least 4 
weeks of fine particle ICS at a constant dose during the run-in. Indeed in a study of severe 
asthma where extra-fine particle HFA-BDP 400µg/day was added on top of fine particle 
fluticasone/salmeterol dry powder inhaler, no further changes were seen in IOS or in the 
alveolar fraction of exhaled nitric oxide.[16]  Another possibility to explain our results is that 
there may have been no further room for improvement in IOS parameters after switching. 
Perhaps using other techniques to look at small airways such as multiple breath nitrogen 
washout or post challenge air trapping on HRCT,[12, 17] might have identified more subtle 
changes which were not detected using IOS. 
A real life effectiveness study using health informatics comparing extra-fine and fine particle 
HFA-BDP formulations over one year observed that overall asthma control was significantly 
better with extra-fine particle HFA-BDP when used at a lower maintenance dose [18], although 
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lung function was not measured. A prospective randomised controlled trial in 473 patients with 
mean FEV1 84% switched patients from their existing chlorofluorocarbon (CFC) suspension 
based fine particle BDP formulation (400-1600ug) to extra-fine particle HFA-BDP at half the 
dose, compared to continuing on an unchanged dose of CFC-BDP, with follow up over 12 
months.[19] The AQLQ score improved significantly with fine versus extra-fine particle BDP, 
while there were no commensurate significant differences in lung function. The lack of any 
significant difference in spirometry including FEF25-75 after switching our study is consistent 
with two other previous head to head trials of extra-fine and fine particle BDP formulations in 
patients who had a baseline mean FEV1 of 84%, which was identical to the present trial.[19, 
20]
In the subgroup of mannitol responsive individuals we observed significant overall effects in 
AHR after switching. Indeed the shift in mannitol PD15 exceeded one doubling dose which is 
taken as being a clinically relevant improvement.[21] Notably in this subgroup the concomitant 
changes seen in PRO’s were also significant and clinically relevant. It has previously been 
shown that dose related changes in AHR in response to ICS are more sensitive than in lung 
function.[22, 23] As both AHR and ACQ are predictors of exacerbations,[6, 7, 9] we believe 
that our data might suggest that switching to extra-fine particle HFA-BDP could also reduce 
the exacerbation burden in the longer term. This is supported by two real life observational 
studies showing better overall asthma control over a one year period of follow up when 
comparing patients who were taking a lower maintenance dose of extra-fine particle versus 
fine particle BDP formulations.[18, 24] 
It is noteworthy that FeNO and blood eosinophils were significantly reduced comparing pre 
and post run-in values while taking a constant dose of fine particle ICS, whereas ACQ and 
mAQLQ were not significantly altered. The reduction in FeNO and eosinophils is likely to 
reflect the putative impact of initial improved adherence to ICS during the run-in period,[25] 
especially for FeNO which exhibits near maximal suppression by low doses of fine particle 
ICS.[26] The lack of any subsequent difference in either FeNO or eosinophils after switching 
to Qvar is consistent with similar findings directly comparing half the dose of extra-fine particle 
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BDP (100ug and 400ug/day) to fine particle BDP.[20] Although in theory concomitant use of 
LTRA might have confounded the underlying asthmatic inflammation, this was only the case 
in 6 patients.
We duly acknowledge the potential weaknesses of our study design. First there was no parallel 
control arm where patients might have continued with an unchanged dose of fine particle HFA-
BDP after run-in, as in the study of Juniper et al.[19] Second our study was powered on ACQ, 
such that we may have missed smaller changes in lung function due to type 2 error, particularly 
for IOS measurements. Third the duration of follow up after switching was relatively short at 8 
weeks. Nonetheless in the Juniper study [19] using a much larger sample size over one year 
there were significant improvements in AQLQ with extra-fine versus fine particle BDP which 
were not associated with commensurate changes in lung function including FEF25-75. It is also 
possible that the observed improvements in PRO’s in our patients might have occurred due 
to progressively enhanced adherence to ICS over the 8 week switch period. However, since 
ACQ was unchanged despite FeNO and eosinophils falling during the run in period on a 
constant dose of ICS, we believe that patients had probably already reached a stable baseline 
level prior to the switch occurring. Hence, we believe the subsequent improvement in ACQ 
after switching to Qvar represents a true treatment effect consequent upon the change in 
particle size. Finally, only a third of our patients had airway hyper-responsiveness at baseline 
after the run in period. This may be explained by mannitol being an indirect challenge agent 
which is more sensitive to ICS than a direct challenge using methacholine.[10, 22] In this 
regards, we did not perform bronchial challenge at screening.
In conclusion, our results show that clinically relevant changes in PRO’s may be associated 
with pragmatic switching from fine particle to extra-fine particle ICS at half the dose. Further 
longer term trials are warranted to prospectively investigate the potential for reducing 
exacerbations when using extra-fine particle ICS formulations in patients with uncontrolled 
persistent asthma. As such, study might also include a parallel control arm where patient 
continue on an unchanged dose of extra fine particle ICS.
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Table 1
 
 Pre run-in           Post run-in
ACQ 1.67 (0.11) 1.65 (0.08)
mAQLQ 5.08 (0.24) 5.34 (0.13)
FEV1 (%) predicted 84 (3) 86 (3)
FEF25-75 (%) predicted 49 (4) 53 (5)
AX (kPa/l) 1.95 (0.30) 1.83 (0.32)
R5 (kPa/l.s) 0.60 (0.04) 0.57 (0.03)
R5-R20 (kPa/l.s) 0.18 (0.03) 0.17 (0.03)
FeNO (ppb) 26 (4) 20 (2)*
Eos (cells/µl) 204 (33) 156 (22)**
Values are presented as means (SEM) except for FeNO and Eos which 
are geometric means (SEM). *p<0.05, **p<0.01. 
The mean clenil equivalent dose of 710µg was maintained throughout the 
run in period.
Table 2
Baseline 4 weeks 8 weeks
ACQ 1.65 (0.08) 1.35 (0.10)* 1.12 (0.12)***
mAQLQ 5.34 (0.13) 5.69 (0.18) 6.03 (0.15)***
FEV1 (%) predicted 86 (3) 84 (2) 86 (3)
FEF25-75 (%) predicted 53 (5) 52 (5) 53 (4)
AX (kPa/l) 1.83 (0.32) 1.88 (0.35) 2.09 (0.36)
R5  (kPa/l.s) 0.57 (0.03) 0.59 (0.04) 0.61 (0.04)
R5-R20  (kPa/l.s) 0.17 (0.03) 0.17 (0.03) 0.19 (0.03)
FeNO (ppb) 20 (2) 23 (3) 24 (2)
Eos (cells/µl) 156 (22) 174 (21) 179 (21)
Values are means (SEM) except for FeNO and Eos as geometric means 
(SEM).* p<0.05, *** p<0.001
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Table 3
 
Baseline 8 weeks
PEF am (l/min) 398 (27) 409 (27)
PEF pm (l/min) 393 (28) 406 (27)
Symptoms am 0.67 (0.11) 0.47 (0.12)*
Symptoms pm 0.69 (0.12) 0.48 (0.14)*
Reliever am 
(puffs/day)
0.63 (0.18) 0.35 (0.13)
Reliever pm 
(puffs/day) 
0.97 (0.20) 0.52 (0.19)*
Values are presented as geometric means (SEM) except 
for PEF.  Symptom scores are 0-3 .*p<0.05
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Figure legends 
Figure 1
CONSORT diagram showing participant flow through the study. 
Figure 2 
Protocol flow chart for the study showing initial run-in period of at least 4 weeks on 
fine particle ICS followed by visits at baseline (post run-in) and after 4 and 8 weeks of 
switching to half the dose of extra-fine particle HFA-BDP. There was a variable step 
down period, where in addition to stopping any LABA, patients if required halved their 
ICS dose at 2 weekly intervals.
Figure 3
Effects of switching from fine to extra-fine particle ICS on patient reported outcomes: 
asthma control questionnaire (ACQ) –the primary end point and mini asthma quality 
of life questionnaire (AQLQ). Data shown as means and SEM.
Figure 4
Scatter plot for ACQ and AQLQ showing individual data post run-in (baseline) on fine 
particle ICS and at 8 weeks after switching to extra-fine particle HFA-BDP, along with 
means and 95% CI.
Figure 5
Mean and SEM values for AQLQ domains after run-in at baseline on fine particle ICS 
and at 4 and 8 weeks after switching to extra-fine particle HFA-BDP. Data shown as 
means and SEM.
Figure 6
Mannitol airway hyper-responsiveness shown as sensitivity (PD15 threshold) and 
reactivity (response dose ratio: RDR) .Values are depicted for post run-in baseline on 
fine particle ICS and after 4 and 8 weeks of switching to extra-fine particle HFA-BDP. 
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Data are shown as geometric means and SEM on a log 2 scale. Overall comparisons 
showed P<0.001 for PD15 and P<0.05 for RDR. 
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CONSORT diagram showing participant flow through the study. 
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Protocol flow chart for the study showing initial run-in period of at least 4 weeks on fine particle ICS followed 
by visits at baseline (post run-in) and after 4 and 8 weeks of switching to half the dose of extra-fine particle 
HFA-BDP. There was a variable step down period, where in addition to stopping any LABA, patients if 
required halved their ICS dose at 2 weekly intervals. 
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Effects of switching from fine to extra-fine particle ICS on patient reported outcomes: asthma control 
questionnaire (ACQ) –the primary end point and mini asthma quality of life questionnaire (AQLQ). Data 
shown as means and SEM. 
218x97mm (300 x 300 DPI) 
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Scatter plot for ACQ and AQLQ showing individual data post run-in (baseline) on fine particle ICS and at 8 
weeks after switching to extra-fine particle HFA-BDP, along with means and 95% CI. 
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Mean and SEM values for AQLQ domains after run-in at baseline on fine particle ICS and at 4 and 8 weeks 
after switching to extra-fine particle HFA-BDP. Data shown as means and SEM. 
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Mannitol airway hyper-responsiveness shown as sensitivity (PD15 threshold) and reactivity (response dose 
ratio: RDR) .Values are depicted for post run-in baseline on fine particle ICS and after 4 and 8 weeks of 
switching to extra-fine particle HFA-BDP. Data are shown as geometric means and SEM on a log 2 scale. 
Overall comparisons showed P<0.001 for PD15 and P<0.05 for RDR. 
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